Pharma WMS is not retail WMS with a temperature label. 21 CFR Part 11, EU GDP, and regional GMP rules demand electronic signatures, immutable audit trails, role-based access, and batch/lot forward-backward traceability as first-class system behaviour — not bolt-ons. Shipsy’s pharma WMS is built for these controls at day one, which is why a global pharma CDMO handling multi-country clinical supply standardised on it across sites.
The finding: compliance gaps live in the WMS, not the SOP
The most common pharma audit findings are not about procedures — they’re about the system that enforced the procedures. FDA 483 letters and EU GDP inspection reports repeatedly cite inadequate electronic record controls, missing audit trails for inventory movements, and unclear user access provisioning.
A compliant pharma WMS has to close those gaps at the transaction level. That means every pick, put-away, adjustment, quarantine, and batch release leaves an audit record tied to an authenticated user, with a reason code, and cannot be silently modified.
Why generic WMS platforms fall short for pharma
Three structural issues.
Audit trail coverage is partial. Generic WMS platforms log major transactions but often skip sub-transactions — barcode rescans, cycle-count adjustments, re-weigh events. 21 CFR Part 11 requires these to be captured with who, what, when, and why.
E-signatures are optional. Pharma processes — lot release, deviation approval, cold chain excursion acceptance — require compliant e-signature workflows with the meaning of the signature on record. Most retail-heritage WMSes treat this as a light add-on.
Batch/lot traceability is one-way. Many systems can answer “which batches are in this shipment” but not “every location, operator, and condition this batch saw from receipt to dispatch.” Forward-backward traceability in a single query is a GDP expectation.
What Shipsy’s pharma WMS does
Shipsy’s WMS for pharma centres on four mechanisms designed into the data model, not layered on.
Transaction-level audit trail. Every state change — inventory adjustment, location change, status flip — writes an immutable audit record. Fields include user, timestamp, reason code, before/after values, and linkage to the authorising document (e.g., deviation report, QA approval).
21 CFR Part 11 e-signature workflows. E-signature steps for critical transactions — batch release, quarantine, destruction — capture printed name, signature meaning, and date/time, with bound signature-to-transaction linkage. Reusable workflows cover the common pharma sign-off points.
GDP-aligned storage conditions and segregation. The WMS enforces storage condition bins (2-8°C, 15-25°C, controlled ambient, -20°C, -80°C) with excursion alerts tied to bin IoT data. Quarantine zones are logically segregated with access-controlled release.
Forward-backward lot traceability. One query returns the full lineage for any lot — inbound ASN, receipt, sampling, QA status, all location moves, all outbound shipments, consignees, and CoA linkage. This cuts recall response from days to minutes.
Pharma WMS compliance checklist
| Requirement area | What a compliant pharma WMS must do |
|---|---|
| 21 CFR Part 11 | Immutable audit trails; compliant e-signatures; user access controls |
| EU GDP | Storage condition enforcement; quarantine segregation; temperature monitoring |
| GMP | Lot traceability forward + backward; CoA linkage; deviation workflow |
| Serialisation | Aggregation/disaggregation at pack/case/pallet; EPCIS event support |
| Data integrity (ALCOA+) | Attributable, legible, contemporaneous, original, accurate records |
| Electronic records retention | Long-term archival with controlled read access |
What pharma ops leaders should do in the next 90 days
Audit your current WMS against ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available). Most generic WMS implementations score well on four of these and poorly on the rest. The gaps show up as inspection findings.
Next, pressure-test your recall response. If a specific lot had to be recalled across every depot and distribution site today, how fast could you produce the forward traceability report? Anything over four hours signals a data-model problem, not an SOP problem.
Finally, evaluate where e-signature workflows are manual (wet signature on a PDF) versus system-enforced. Each manual hand-off is an audit risk and a cycle-time tax. Shipsy’s pharma WMS digitises the common sign-off chains out of the box.
For cold chain excursion handling that complements WMS, see pharma cold chain management. For the broader pharma vertical overview, see how Shipsy fits pharma. The underlying product is covered at Shipsy WMS.